Trial Profile
Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Autoimmune disorders; Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors Octapharma
- 15 Jun 2023 Results of subgroup analysis (n= 3,846) assessing Tolerability and Safety of Intravenous Immunoglobulins (5% and 10%) for the Treatment of Patients with Secondary Immunodeficiencies presented at the 28th Congress of the European Haematology Association
- 02 Jan 2020 Status changed from active, no longer recruiting to completed.
- 19 Nov 2018 Status changed from recruiting to active, no longer recruiting.